Profilo
Morgan Sheng is a Professor at the Massachusetts Institute of Technology.
He was previously an Independent Director at Prevail Therapeutics, Inc. from 2019 to 2021 and a Vice President-Neuroscience at Genentech, Inc. He holds a doctorate degree from Harvard University and the University of London, and an undergraduate degree from the University of Oxford.
Posizioni attive di Morgan Sheng
| Società | Posizione | Inizio |
|---|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Corporate Officer/Principal | - |
Precedenti posizioni note di Morgan Sheng
| Società | Posizione | Fine |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Direttore/Membro del Consiglio | 22/01/2021 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Formazione di Morgan Sheng
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prevail Therapeutics, Inc.
Prevail Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutics for neurodegenerative diseases | Health Technology |
















